Intraabdominal Infections, Nosocomial Infection, Pneumonia, Bacterial, Urinary Tract Infection
Conditions
Keywords
Pneumonia, Bacterial, Nosocomial Infection, Intraabdominal Infections, Urinary Tract Infection, Ventilator-associated pneumonia, Doripenem, Doribax, Filipino
Brief summary
The purpose of this study is to assess the safety and effectiveness of doripenem treatment among Filipino patients with nosocomial pneumonia, complicated intra-abdominal infections, and complicated urinary tract infection.
Detailed description
This is an open-label study (all people know the identity of the treatment assigned), multi-center (conducted at multiple sites), and observational (study in which the investigators/physicians observe the patients and measure their outcomes) study to evaluate the safety and effectiveness of doripenem for the treatment of nosocomial pneumonia, complicated intra-abdominal infections and complicated urinary tract infection among Filipino patients. Safety evaluations for adverse events, clinical laboratory tests, physical examination, and concomitant medications will be monitored throughout the study. The total duration of study for each patient will be approximately for 3 years.
Interventions
DRUGNo intervention
This is an observational study. Doripenem will be administered as per the recommended dose, ie, 500 mg, intravenously (ie, in the vein), for every 8 hours. Duration of treatment with doripenem: for nosocomial pneumonia including ventilator-associated pneumonia patients: 7 to 14 days; for complicated intra-abdominal infection patients: 5 to 14 days; for complicated urinary tract infection, including pyelonephritis (bacterial infection of the kidneys) patients: 10 days.
Sponsors
Janssen Pharmaceutica
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who are diagnosed with nosocomial pneumonia including ventilator-associated pneumonia, complicated intra-abdominal infections or complicated urinary tract infection * Patients who are eligible for doripenem treatment
Exclusion criteria
* Pregnant or lactating females * Patients with hypersensitivity to doripenem and/or its derivatives * Known at study entry to have an infection caused by pathogen(s) resistant to doripenem * Patients taking probenecid * History of severe allergies to certain antibiotics such as penicillins, cephalosporins, and carbapenems * Severe impairment of renal function including a calculated creatinine clearance of less than 10 mL per minute, requirement for peritoneal dialysis, hemodialysis or hemofiltration, or oliguria (less than 20 mL urine output per hour over 24 hours)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients with incidence of adverse events | Up to 30 days after the last dose of study medication |
| Number of patients with incidence of discontinuation of study medication due to adverse events | Up to 30 days after the last dose of study medication |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with nosocomial pneumonia (including ventilator-associated pneumonia patients) who achieved clinical cure at test-of-cure visit | Up to 7 days | Clinical cure will be defined as resolution of all signs and symptoms or improvement or lack of progression of all abnormalities to such extent that no further antimicrobial therapy is necessary. Clinical failure will be defined as persistence or worsening signs and symptoms or emergence of new signs and symptoms of new infection and will need antimicrobial treatment aside from the study medication. |
| Number of patients with complicated urinary tract infection who achieved clinical cure at test-of-cure visit | Up to 7 days | Clinical cure will be defined as resolution of all signs and symptoms or improvement or lack of progression of all abnormalities to such extent that no further antimicrobial therapy is necessary. Clinical failure will be defined as persistence or worsening signs and symptoms or emergence of new signs and symptoms of new infection and will need antimicrobial treatment aside from the study medication. |
| Number of patients with complicated intra-abdominal infections who achieved clinical cure at test-of-cure visit | Up to 21 days | Clinical cure will be defined as resolution of all signs and symptoms or improvement or lack of progression of all abnormalities to such extent that no further antimicrobial therapy is necessary. Clinical failure will be defined as persistence or worsening signs and symptoms or emergence of new signs and symptoms of new infection and will need antimicrobial treatment aside from the study medication. |
Countries
Philippines
Outcome results
None listed